Literature DB >> 33010259

Screening for SARS-CoV-2 antibodies among healthcare workers in a university hospital in southern France.

Chloé Dimeglio1, Fabrice Herin2, Marcel Miedougé3, Jean-Pierre Cambus4, Florence Abravanel5, Jean-Michel Mansuy3, Jean-Marc Soulat2, Jacques Izopet5.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 33010259      PMCID: PMC7526656          DOI: 10.1016/j.jinf.2020.09.035

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


× No keyword cloud information.
Dear Editor, A recent study in this journal reported characteristics of healthcare workers (HCW) infected with SARS-CoV-2 in order to identify new cases as early as possible. Here, we aimed to determine the serological status of HCW after the first wave of the epidemic, and the extent of their protective immunity. This is particularly important as this population will always be in the front line combatting the probable continuation of the present epidemic. , HCW can also be a source of transmission, introducing virus into a hospital harbouring many susceptible patients or co-workers. From June 10, 2020 to July 10, 2020, 1 to 2 months after the end of lockdown in France, everyone who worked at Toulouse University Hospital (n = 16 571) was invited for screening total serum antibodies by enzyme linked immunosorbent assay (ELISA) kit supplied by Wantai (Beijing Wantai Biological Pharmacy Enterprise Co., Ltd, China). The participation rate was 53% without associated bias. All sera from ELISA-positive personnel were screened for neutralizing antibodies. The 8758 HCW who took part in the study (1719 (19.6%) males; 7039 females (80.4%)) had a median age of 40 years (interquartile range [IQR] 32–50). The ELISA test indicated that 276 HCW had SARS-CoV-2 antibodies, corresponding to an overall seroprevalence of 3.2% (95% confidence interval [CI] 2.8%−3.5%). Seroprevalences in CHU units ranged from 0.7% to 7.3% (median: 3.6%) (Fig. 1. A) and varied from 0% to 9.2% (median: 3.4%) according to the professional status (Fig. 1.B). Physiotherapists were the caregivers with the highest seroprevalence rate (9.2%), just ahead of psychologists (5.5%) and physicians (5%). Midwives (0.9%), biologists (1.3%) and chemists (2.1%) had among the lowest seroprevalence rates. One third of the 276 COVID-positive HCW (84; 30.4%) were asymptomatic and 95.3% of HCW with SARS-CoV-2 antibodies had neutralizing antibodies (median 16, range: <2 to 256). Women had lower neutralizing antibody titers than men (p = 0.02) (Fig. 2. A) and asymptomatic HCW had lower neutralizing antibody titers than symptomatic workers (p<0.01) (Fig. 2.B).
Fig. 1

Seroprevalence by ELISA in CHU units (A) and by occupation (B).

Fig. 2

Neutralizing Ab titers in ELISA positive-testing individuals.

Seroprevalence by ELISA in CHU units (A) and by occupation (B). Neutralizing Ab titers in ELISA positive-testing individuals. While only 3.2% of HCW developed total SARS-CoV-2 antibodies there was substantial variation between individual units. A previous study based on predictive models estimated that the burden of SARS-CoV-2 in Occitania was between 2.3% (95% CI: 1.4–4.2) and 2.4% (95% CI: 1.5–4.8). Our results are within the confidence intervals of these forecasts, suggesting that the virus load in the hospital population was globally similar to that of the regional population. Our seroprevalence results are higher than those found for HCW in a German reference hospital but similar to those of the study done in Wuhan approximately 4–8 weeks after the peak of infection. These discrepancies could be linked to differences in the level of SARS-CoV-2 transmission in hospital setting from patients to HCW or between co-workers, but also within the community reflecting the local epidemics. However, the seroprevalence of staff working in high-risk units, such as emergency medicine (2.9%) and intensive care (3.1%), were below the median. The Public Health service (7.3%), the unit in charge of health training schools (6.9%), and the Infectious Diseases unit (6.7%) were among the most affected (seroprevalence >6%). Like us, the German study found that the seroprevalence of SARS-CoV-2 in the group most at risk (1.2%) was lower than in the group at medium risk (5.4%). The low seroprevalence in the most exposed units might indicate that the local hygiene standards were more rigorously enforced, while the higher seroprevalence in other lower-exposure units suggests that awareness of COVID-19 transmission must be improved, even in non−COVID-19 units. Perhaps our most important finding is that nearly one third of HCW who developed antibodies were asymptomatic. This is consistent with the results of a recent study reporting that 35.5% of health professionals from two tertiary-level maternity units in London, UK were asymptomatic and could have important implications for staff-to-staff and staff-to-patient transmission, since the asymptomatic individuals were not quarantined. In our study, the units with the highest proportions of asymptomatic seropositive staff were the Children's unit (57.1%), the Emergency Unit (55.6%) and General Administration (46.7%); these three units had seroprevalences among the lowest in the hospital. One hypothesis assumes that the hygiene guidelines were particularly well respected in these units. Another is that infected, asymptomatic individuals were less contagious than infected, symptomatic people. Most of the HCW who test positive by ELISA had neutralizing antibodies with titers of 2 to 256. However, we do not know the titre of neutralizing antibodies that would protect recovered patients from a secondary infection. Analogy with the common cold coronaviruses would suggest that protective immunity is incomplete and temporary, lasting only several months to a few years. We found that the 13 individuals harbouring total anti-SARS-CoV-2 antibodies but no neutralizing antibodies included 12 who were asymptomatic. The fact that asymptomatic individuals had significantly lower neutralizing antibodies titers than people who had contracted a symptomatic infection suggests that the protective immunity is lower in asymptomatic people and may eventually lead to reinfection with SARS-CoV-2. This relationship is supported by a study on asymptomatic SARS-CoV-2 cases who had a lower antibody response and titres that waned quickly. Although several recommendations to protect HCW and restrict the spread of SARS-CoV-2 in hospital setting have been made, our study did not evaluate adherence to local guidelines. The variation of the seroprevalence of SARS-CoV-2 in HCW could be due to how well the hygiene measures installed to combat the transmission of SARS-CoV-2 are adhered to. Transmission could be reduced by enhancing infection prevention training and communication within hospitals, particularly in units with little or no exposure to the virus and by introducing audits of hygiene practices. This is particularly important due to the large proportion of asymptomatic cases and the risk of uncontrolled transmission which is not detected.

Declaration of Competing Interest

The authors declare no competing interests.
  9 in total

1.  Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections.

Authors:  Quan-Xin Long; Xiao-Jun Tang; Qiu-Lin Shi; Qin Li; Hai-Jun Deng; Jun Yuan; Jie-Li Hu; Wei Xu; Yong Zhang; Fa-Jin Lv; Kun Su; Fan Zhang; Jiang Gong; Bo Wu; Xia-Mao Liu; Jin-Jing Li; Jing-Fu Qiu; Juan Chen; Ai-Long Huang
Journal:  Nat Med       Date:  2020-06-18       Impact factor: 53.440

2.  The time course of the immune response to experimental coronavirus infection of man.

Authors:  K A Callow; H F Parry; M Sergeant; D A Tyrrell
Journal:  Epidemiol Infect       Date:  1990-10       Impact factor: 2.451

3.  A cross-sectional study of immune seroconversion to SARS-CoV-2 in frontline maternity health professionals.

Authors:  S Bampoe; D N Lucas; G Neall; P Sceales; R Aggarwal; K Caulfield; D Siassakos; P M Odor
Journal:  Anaesthesia       Date:  2020-08-10       Impact factor: 6.955

4.  Estimating the burden of SARS-CoV-2 in France.

Authors:  Henrik Salje; Cécile Tran Kiem; Noémie Lefrancq; Noémie Courtejoie; Paolo Bosetti; Juliette Paireau; Alessio Andronico; Nathanaël Hozé; Jehanne Richet; Claire-Lise Dubost; Yann Le Strat; Justin Lessler; Daniel Levy-Bruhl; Arnaud Fontanet; Lulla Opatowski; Pierre-Yves Boelle; Simon Cauchemez
Journal:  Science       Date:  2020-05-13       Impact factor: 47.728

5.  SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients.

Authors:  Johannes Korth; Benjamin Wilde; Sebastian Dolff; Olympia E Anastasiou; Adalbert Krawczyk; Michael Jahn; Sebastian Cordes; Birgit Ross; Stefan Esser; Monika Lindemann; Andreas Kribben; Ulf Dittmer; Oliver Witzke; Anke Herrmann
Journal:  J Clin Virol       Date:  2020-05-13       Impact factor: 3.168

6.  Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study.

Authors:  Marina Pollán; Beatriz Pérez-Gómez; Roberto Pastor-Barriuso; Jesús Oteo; Miguel A Hernán; Mayte Pérez-Olmeda; Jose L Sanmartín; Aurora Fernández-García; Israel Cruz; Nerea Fernández de Larrea; Marta Molina; Francisco Rodríguez-Cabrera; Mariano Martín; Paloma Merino-Amador; Jose León Paniagua; Juan F Muñoz-Montalvo; Faustino Blanco; Raquel Yotti
Journal:  Lancet       Date:  2020-07-06       Impact factor: 79.321

7.  Clinical presentation of Covid-19 in health care workers from a French University Hospital.

Authors:  Aude Jary; Philippe Flandre; Agnès Chabouis; Séverine Nguyen; Stéphane Marot; Sonia Burrel; David Boutolleau; Vincent Calvez; Anne-Geneviève Marcelin; Martine Louet
Journal:  J Infect       Date:  2020-06-21       Impact factor: 6.072

8.  Author Correction: Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China.

Authors:  Xin Xu; Jian Sun; Sheng Nie; Huiyuan Li; Yaozhong Kong; Min Liang; Jinlin Hou; Xianzhong Huang; Dongfeng Li; Tean Ma; Jiaqing Peng; Shikui Gao; Yong Shao; Hong Zhu; Johnson Yiu-Nam Lau; Guangyu Wang; Chunbao Xie; Li Jiang; Ailong Huang; Zhenglin Yang; Kang Zhang; Fan Fan Hou
Journal:  Nat Med       Date:  2020-09       Impact factor: 53.440

9.  Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study.

Authors:  Silvia Stringhini; Ania Wisniak; Giovanni Piumatti; Andrew S Azman; Stephen A Lauer; Hélène Baysson; David De Ridder; Dusan Petrovic; Stephanie Schrempft; Kailing Marcus; Sabine Yerly; Isabelle Arm Vernez; Olivia Keiser; Samia Hurst; Klara M Posfay-Barbe; Didier Trono; Didier Pittet; Laurent Gétaz; François Chappuis; Isabella Eckerle; Nicolas Vuilleumier; Benjamin Meyer; Antoine Flahault; Laurent Kaiser; Idris Guessous
Journal:  Lancet       Date:  2020-06-11       Impact factor: 79.321

  9 in total
  7 in total

1.  Hospital-wide SARS-CoV-2 antibody screening of 4840 staff members in a University Medical Center in France: a cross-sectional study.

Authors:  Marion Pierson-Marchandise; Sandrine Castelain; Cassandra Chevalier; Etienne Brochot; Jean-Luc Schmit; Momar Diouf; Olivier Ganry; Maxime Gignon
Journal:  BMJ Open       Date:  2022-05-11       Impact factor: 3.006

2.  Evaluation of Three Quantitative Anti-SARS-CoV-2 Antibody Immunoassays.

Authors:  Sabine Chapuy-Regaud; Marcel Miédougé; Florence Abravanel; Isabelle Da Silva; Marion Porcheron; Judith Fillaux; Chloé Diméglio; Jacques Izopet
Journal:  Microbiol Spectr       Date:  2021-12-22

3.  Seroepidemiology of SARS-CoV-2 in healthcare personnel working at the largest tertiary COVID-19 referral hospitals in Mexico City.

Authors:  Vanessa Dávila-Conn; Maribel Soto-Nava; Yanink N Caro-Vega; Héctor E Paz-Juárez; Pedro García-Esparza; Daniela Tapia-Trejo; Marissa Pérez-García; Pablo F Belaunzarán-Zamudio; Gustavo Reyes-Terán; Juan G Sierra-Madero; Arturo Galindo-Fraga; Santiago Ávila-Ríos
Journal:  PLoS One       Date:  2022-03-17       Impact factor: 3.240

4.  Decreased Efficiency of Neutralizing Antibodies from Previously Infected or Vaccinated Individuals against the B.1.617.2 (Delta) SARS-CoV-2 Variant.

Authors:  Chloé Dimeglio; Fabrice Herin; Isabelle Da-Silva; Caroline Gernigon; Marion Porcheron; Sabine Chapuy-Regaud; Jacques Izopet
Journal:  Microbiol Spectr       Date:  2022-07-05

5.  One year later: SARS-CoV-2 immune response and vaccination of healthcare workers post-infection.

Authors:  Chloé Dimeglio; Fabrice Herin; Marcel Miedougé; Isabelle Da-Silva; Marion Porcheron; Guillaume Martin-Blondel; Jean-Marc Soulat; Jacques Izopet
Journal:  J Infect       Date:  2021-06-18       Impact factor: 38.637

6.  The real seroprevalence of SARS-CoV-2 in France and its consequences for virus dynamics.

Authors:  Chloé Dimeglio; Jean-Michel Loubes; Marcel Miedougé; Fabrice Herin; Jean-Marc Soulat; Jacques Izopet
Journal:  Sci Rep       Date:  2021-06-15       Impact factor: 4.379

7.  Antibody titers and protection against a SARS-CoV-2 infection.

Authors:  Chloé Dimeglio; Fabrice Herin; Guillaume Martin-Blondel; Marcel Miedougé; Jacques Izopet
Journal:  J Infect       Date:  2021-09-21       Impact factor: 6.072

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.